REAnimation Low Immune Status Markers (REALISM)
The fact that sepsis disrupts immune system homeostasis by inducing an initial cytokine storm, that participates to occurrence of organ failures and early death, followed by a compensatory anti-inflammatory response leading to immunosuppression, is now well established. This immunomodulating response results in a higher risk of secondary infections and is associated to 2/3 of deaths related to septic shocks. Follow up of patients' immune status with time is crucial to guide therapy management. Objective of REALISM project is to demonstrate existence of this immunosuppression phase, by providing strong epidemiologic data for septic shock patients, but also by extension to other situations of inflammatory aggressions like severe severe trauma or burns, or major surgery. This project will provide tools to predict occurrence of secondary infections and guide patient management by comparing innovating immunomonitoring tools to reference tests non already adapted to a routine patient management.
Targeted populations are adult patients hospitalized for septic shock, severe trauma (including severe burn) or major surgery and healthy volunteers, whom blood samples will serve to validate reference intervals of the two reference tests.
調査の概要
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
LYON cedex 03、フランス、69437
- Service d'Anesthésie Réanimation - Hôpital Edouard Herriot
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion criteria for patients
- Patient or next of kin having been informed of the conditions of the study and having signed the informed consent form
Patient hospitalized for :
- Septic shock
- Severe trauma (including severe burn)
- Major surgery
Inclusion criteria for healthy volunteers
- Normal clinical examination
- Signed informed consent form
- Person with social security insurance
Exclusion criteria for patients
- Patient with severe neutropenia (neutrophil count <0.5 g/l)
- Patients receiving immunosuppressive therapy
- Patients receiving corticosteroids (IV or Per os)
- Use of therapeutic antibodies
- Hematological disease under treatment, or treated within 5 years before inclusion
- End of chemotherapy within the 6 months prior to inclusion
- Patient with innate or acquired immune deficiency (for example severe combined immunodeficiency, HIV or AIDS, any stage)
- Patients for whom a care limitation was pronounced at time of enrolment
- Anticipated length of stay before discharge from the ICU is estimated at less than 48 hours
- Participation in an intervention study
- Extra-corporeal circulation in the month preceding inclusion in case of cardiac surgery
- Pregnant or breastfeeding women
- Patient with no social security insurance, with restricted liberty or under legal protection
Exclusion criteria for healthy volunteers
- Person with an infectious syndrome during the last 90 days
- Extreme physical stress within the last week
Person having received within the last 90 days, a treatment based on
- Antivirals
- Antibiotics
- Antiparasitics
- Antifungics
- Person having received within the last 15 days, a treatment based on non-steroidal anti-inflammatory drugs (NSAIDs)
Person having received within the last 24 months, a treatment based on
- Immunosuppressive therapy
- Corticosteroids (IV or Per os)
- Therapeutic antibodies
- Chemotherapy
History of :
- innate or acquired immune deficiency
- Hematological disease
- Solid tumor
- Severe chronic disease
- Surgery or hospitalization within the last 2 years
- Pregnancy within the last year
- Participation to a phase I clinical assay during the last year
- Pregnant or breastfeeding women
- Person with restricted liberty or under legal protection
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:診断
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:Blood sampling
Blood sampling will be performed in all patients and healthy volunteers
|
Specific Blood sampling will be performed in patients and healthy volunteers
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Percentage of patients meeting the definition of of injury-induced-immunosuppression
時間枠:Up to 2 months after injury
|
The immunosuppression status will be determined from two immunological reference tests: (1) lymphocyte proliferation in response to ex vivo T cell stimulation (adaptive immunity) (Poujol et al., 2014) and (2) the production of tumor necrosis factor (TNF) by monocytes in response to ex vivo stimulation by lipopolysaccharide (LPS) (innate immunity) (Duffy et al., 2014).
The values measured will be defined as normal or abnormal, depending on whether they are within reference intervals (RI) derived from an independent set of healthy volunteers.
For this purpose, the definition of immunosuppression will be: an abnormal result in at least one of the two "reference" tests (outside the reference intervals defining normal values), and on at least two consecutive samples.
The same reference test must be abnormal in two successive samples examined for the patient to be considered immunosuppressed.
|
Up to 2 months after injury
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Proportion of patients with a deficiency of the innate or adaptive immunity
時間枠:Up to 2 months after injury
|
Intensity of the innate immune deficiency will be measured using the production of TNF by monocytes in response to ex vivo stimulation by LPS (Duffy et al., 2014). Intensity of the adaptive immune deficiency will be measured using the lymphocyte proliferation in response to ex vivo T cell stimulation (Poujol et al., 2014). The values measured will be defined as normal or abnormal, depending on whether they are within reference intervals derived from an independent set of healthy volunteers. We will describe for all groups of patients:
|
Up to 2 months after injury
|
Comparison of performance of the reference tests and new biomarkers for the diagnosis of immunosuppression
時間枠:Up to one week after injury
|
Reference tests being non-standardized and cumbersome to implement, and time to results being incompatible with clinical practice, the use of simpler and quicker tests, based on the use of new biomarkers, would allow the individualization of patient management based on the patient's immune status.
One of the secondary objectives is to evaluate the performance of new biomarkers compared to the two reference tests to diagnose immunosuppression.
Different types of markers and tests will be evaluated: Viral reactivation markers, host-response markers, immune functional assays, immunophenotyping.
|
Up to one week after injury
|
Correlation between the immunosuppression status and the incidence of healthcare-associated infections
時間枠:Up to 28 days after injury
|
To evaluate the association between the immunosuppression status as defined in primary objective and the occurrence of secondary infections related to healthcare, the association of the immunosuppression status upon the occurrence of secondary infection will be examined first, and secondly any possible association between the levels of each of the reference tests and the occurrence of secondary infections will be characterized.
In this analysis, a secondary infection related to healthcare will be defined as an infection occurring after inclusion in the study, between inclusion and day 28.
|
Up to 28 days after injury
|
Correlation between immunosuppression and mortality
時間枠:Up to 90 days after injury
|
We will examine the association between immunosuppression (as defined in the primary objective) and in-hospital mortality.
Association will be evaluated par measuring occurrence of mortality at days 14, 28, 60 and 90, in the different groups.
|
Up to 90 days after injury
|
Comparison of immune status before and after surgery in the population of surgical patients
時間枠:Up to 2 months after surgery
|
The possibility of taking a sample before surgical stress should allow measurements of the impact of the procedure on the host response, and especially on any subsequent onset of immunosuppression.
Oncological pathologies and treatments implemented prior to surgery may also be associated with immunosuppression, and for this reason patients hospitalized for cancer surgery will be compared to those hospitalized for vascular surgery.
Impact of surgery on immunosuppression will be measured by comparing immune status as defined by the reference tests, in the population of surgical patients before and after surgery.
|
Up to 2 months after surgery
|
協力者と研究者
スポンサー
出版物と役立つリンク
一般刊行物
- Bodinier M, Peronnet E, Brengel-Pesce K, Conti F, Rimmelé T, Textoris J, Vedrine C, Quemeneur L, Griffiths AD, Tan LK, Venet F, Maucort-Boulch D, Monneret G; REALISM study group. Monocyte Trajectories Endotypes Are Associated With Worsening in Septic Patients. Front Immunol. 2021 Nov 29;12:795052. doi: 10.3389/fimmu.2021.795052. eCollection 2021.
- Mallet F, Diouf L, Meunier B, Perret M, Reynier F, Leissner P, Quemeneur L, Griffiths AD, Moucadel V, Pachot A, Venet F, Monneret G, Lepape A, Rimmele T, Tan LK, Brengel-Pesce K, Textoris J. Herpes DNAemia and TTV Viraemia in Intensive Care Unit Critically Ill Patients: A Single-Centre Prospective Longitudinal Study. Front Immunol. 2021 Nov 2;12:698808. doi: 10.3389/fimmu.2021.698808. eCollection 2021.
- Venet F, Textoris J, Blein S, Rol ML, Bodinier M, Canard B, Cortez P, Meunier B, Tan LK, Tipple C, Quemeneur L, Reynier F, Leissner P, Vedrine C, Bouffard Y, Delwarde B, Martin O, Girardot T, Truc C, Griffiths AD, Moucadel V, Pachot A, Monneret G, Rimmele T; REALISM study group. Immune Profiling Demonstrates a Common Immune Signature of Delayed Acquired Immunodeficiency in Patients With Various Etiologies of Severe Injury. Crit Care Med. 2022 Apr 1;50(4):565-575. doi: 10.1097/CCM.0000000000005270.
- Rol ML, Venet F, Rimmele T, Moucadel V, Cortez P, Quemeneur L, Gardiner D, Griffiths A, Pachot A, Textoris J, Monneret G; REALISM study group. The REAnimation Low Immune Status Markers (REALISM) project: a protocol for broad characterisation and follow-up of injury-induced immunosuppression in intensive care unit (ICU) critically ill patients. BMJ Open. 2017 Jun 21;7(6):e015734. doi: 10.1136/bmjopen-2016-015734.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 69HCL15_0379
- 2015-A01293-46 (その他の識別子:ID-RCB)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
Blood samplingの臨床試験
-
University of UtahAlbert Einstein College of Medicine; University of California, San Francisco; National Human Genome... と他の協力者完了新生児スクリーニング
-
Ischemia Care LLC完了虚血性脳卒中 | 心房細動 | 血栓性脳卒中 | 一過性脳虚血発作 | 心塞栓性脳卒中 | 脳底動脈の脳卒中 | 一過性脳血管イベントアメリカ
-
Applied Science & Performance Institute完了
-
Bedford Hospital NHS TrustAnglia Ruskin Universityわからない